Daniel S Parks

US Patent:

7115598, Oct 3, 2006

Filed:

Apr 21, 2004

Appl. No.:

10/829040

Inventors:

Tianbao Lu - Churchville PA, US
Karen L. Milkiewicz - Exton PA, US
Pierre Raboisson - Mechelen, BE
Maxwell David Cummings - Wayne PA, US
Raul R. Calvo - Royersford PA, US
Daniel J. Parks - Downingtown PA, US
Juan Jose Marugan Sanchez - Downingtown PA, US
Joan Gushue - Conshohocken PA, US
Kristi Leonard - West Chester PA, US

Assignee:

Ortho-McNeil Pharmaceutical, Inc. - Raritan NJ

International Classification:

C07D 243/14
A61K 31/55

US Classification:

514221, 540506, 540509

Abstract:

The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I:R, R, R, R, R, Rand M are defined herein;X is a bivalent radical of: an alkane, a cycloalkane, an optionally-substituted arene, an optionally-substituted heteroarene, an optionally-substituted arylalkane or an optionally-substituted heteroarylalkane; andRis —COR, —COM, —OH, —NHR, —SOR, —NHCONHR, optionally-substituted amidino or optionally-substituted guanidino;or R—X— is hydrogen or an electron pair;Ris oxygen or —NRR;Ris cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, or a saturated or partially unsaturated heterocycle, each of which is optionally substituted; andR, Rand Rare independently hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, a saturated or partially unsaturated heterocycle, cycloalkylalkyl, aralkyl or heteroarylalkyl, each of which is optionally substituted; or Rand R, together with the carbon atom to which they are attached form a 3- to 7-membered carbocyclic ring optionally substituted 1 to 3 times with R.

US Patent:

7446210, Nov 4, 2008

Filed:

Oct 24, 2005

Appl. No.:

11/257208

Inventors:

Tianbao Lu - Churchville PA, US
Tho V. Thieu - Ambler PA, US
Yu-Kai Lee - Exton PA, US
Daniel J. Parks - Downingtown PA, US
Thomas P. Markotan - Morgantown PA, US
Wenxi Pan - Glenmore PA, US
Karen L. Milkiewicz - Exton PA, US
Mark R. Player - Phoenixville PA, US

Assignee:

Janssen Pharmaceutica N.V. - Beerse

International Classification:

C07D 207/00
C07D 213/00
C07D 231/00
C07D 231/54
C07D 239/02
C07D 241/04
C07D 265/28
C07D 295/00
C07D 487/00

US Classification:

5483581, 544 98, 544298, 544383, 546 1, 5483561, 548400

Abstract:

The present invention is directed to novel compounds of Formula I:.

US Patent:

7612211, Nov 3, 2009

Filed:

Dec 12, 2007

Appl. No.:

11/954647

Inventors:

Wing S. Cheung - Plainsboro NJ, US
Daniel J. Parks - Downingtown PA, US
William H. Parsons - Belle Mead NJ, US
Sharmila Patel - Jamison PA, US
Mark R. Player - Phoenixville PA, US

Assignee:

Janssen Pharmaceutica N.V. - Beerse

International Classification:

A61K 31/4184
C07D 235/12

US Classification:

5483101, 514394

Abstract:

The invention is directed to compounds of Formula (I):.

US Patent:

20060235007, Oct 19, 2006

Filed:

Jun 14, 2006

Appl. No.:

11/452861

Inventors:

Tianbao Lu - Churchville PA, US
Karen Milkiewicz - Exton PA, US
Pierre Raboisson - Mechelen, BE
Maxwell Cummings - Wayne PA, US
Raul Calvo - Royersford PA, US
Daniel Parks - Downingtown PA, US
Louis LaFrance - West Chester PA, US
Juan Marugan Sanchez - Downingtown PA, US
Joan Gushue - Conshohocken PA, US
Kristi Leonard - West Chester PA, US

International Classification:

A61K 31/5513
C07D 403/02
C07D 413/02
C07D 243/18

US Classification:

514221000, 540505000

Abstract:

The present invention is directed to novel 1,4-diazepines, pharmaceutical compositions thereof and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:

US Patent:

20170057929, Mar 2, 2017

Filed:

Aug 23, 2016

Appl. No.:

15/244372

Inventors:

- Beerse, BE
Rui Zhang - Belle Mead NJ, US
Yue-Mei Zhang - Wellesley MA, US
Bin Zhu - Newtown PA, US
Michael H. Parker - Chalfont PA, US
Donald W. Ludovici - Quakertown PA, US
Daniel J. Parks - Pepperell MA, US
Bart L. DeCorte - Southampton PA, US
Michael N. Greco - Lansdale PA, US

Assignee:

Janssen Pharmaceutica NV - Beerse

International Classification:

C07D 235/18
C07C 53/18
C07D 401/14
C07D 405/14
C07D 409/14
C07D 405/04
C07D 417/14
C07D 471/08
C07D 409/10
C07D 401/06
C07D 417/06
C07D 405/06
C07D 401/04
C07D 403/04

Abstract:

The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.